BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 15597347)

  • 1. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.
    Moog R; Fröhlich A; Mayaudon V; Lin L
    J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.
    Isola H; Kientz D; Aleil B; Laeuffer P; Weil J; Wiesel ML; Laforêt M; Lin L; Mayaudon V; Cazenave JP
    Vox Sang; 2006 Feb; 90(2):128-30. PubMed ID: 16430671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
    Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
    Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
    Lozano M; Galan A; Mazzara R; Corash L; Escolar G
    Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
    Pineda A; McCullough J; Benjamin RJ; Cable R; Strauss RG; Burgstaler E; Porter S; Lin L; Metzel P; Conlan MG;
    Transfusion; 2006 Apr; 46(4):562-71. PubMed ID: 16584432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.
    Apelseth TØ; Bruserud Ø; Wentzel-Larsen T; Bakken AM; Bjørsvik S; Hervig T
    Transfusion; 2007 Apr; 47(4):653-65. PubMed ID: 17381624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days.
    Shanwell A; Diedrich B; Falker C; Jansson B; Sandgren P; Sundkvist L; Svensson L; Vesterinen M; Gulliksson H
    Transfusion; 2006 Jun; 46(6):973-9. PubMed ID: 16734814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
    Picker SM; Oustianskaia L; Schneider V; Gathof BS
    Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates.
    Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
    Transfusion; 2008 Oct; 48(10):2114-21. PubMed ID: 18647365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Storage of platelet concentrates from pooled buffy coats made of fresh and overnight-stored whole blood processed on the novel Atreus 2C+ system: in vitro study.
    Sandgren P; Callaert M; Shanwell A; Gulliksson H
    Transfusion; 2008 Apr; 48(4):688-96. PubMed ID: 18194379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quality of platelet concentrates produced by COBE Spectra and Trima Accel cell separators during storage for 7 days as assessed by in vitro methods.
    Tynngård N; Lindahl TL; Trinks M; Studer M; Berlin G
    Transfusion; 2008 Apr; 48(4):715-22. PubMed ID: 18208416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
    Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
    Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods.
    Ali SF
    Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the automated collection and extended storage of apheresis platelets in additive solution.
    Johnson L; Winter KM; Hartkopf-Theis T; Reid S; Kwok M; Marks DC
    Transfusion; 2012 Mar; 52(3):503-9. PubMed ID: 21880041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequently used plateletpheresis techniques result in variable target yields and platelet recruitment of donors.
    Strasser EF; Schuster M; Egler K; Bauer J; Weisbach V; Ringwald J; Zimmermann R; Zingsem J; Eckstein R
    Transfusion; 2005 May; 45(5):788-97. PubMed ID: 15847670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
    Picker SM; Steisel A; Gathof BS
    Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
    Cardigan R; Sutherland J; Garwood M; Bashir S; Turner C; Smith K; Hancock V; Wiltshire M; Pergande C; Williamson LM
    Vox Sang; 2008 Feb; 94(2):103-12. PubMed ID: 18034786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
    Picker SM; Tauszig ME; Gathof BS
    Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rest period does not affect in vitro storage properties in apheresis platelets collected from the buffy coat layer.
    Wagner SJ; Seetharaman S; Kurtz J
    Transfusion; 2012 Nov; 52(11):2427-31. PubMed ID: 22452313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.